Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Cardiology Journal
MENU
Shortcuts Submit an article CJ Guide for Authors (new) Recent articles Special collections Ahead Of Print APIS-S Online Calculator OCT Contrast Calculator Reviewers 2022

open access

Vol 29, No 2 (2022)
Review Article
Submitted: 2021-10-17
Accepted: 2021-12-03
Published online: 2021-12-28
View PDF Download PDF file View HTML
Get Citation

Continuous-flow left ventricular assist device: Current knowledge, complications, and future directions

Javier Castrodeza12, Carlos Ortiz-Bautista12, Francisco Fernández-Avilés123
DOI: 10.5603/CJ.a2021.0172
·
Pubmed: 34967940
·
Cardiol J 2022;29(2):293-304.
Affiliations
  1. Cardiology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
  2. CIBER de Enfermedades Cardiovasculares (CIBER - CV), Spain
  3. Universidad Complutense, Madrid, Spain

open access

Vol 29, No 2 (2022)
Review articles — Interventional cardiology
Submitted: 2021-10-17
Accepted: 2021-12-03
Published online: 2021-12-28

Abstract

Long-term continuous-flow left ventricular assist devices have become a real alternative to heart transplantation in patients with advanced heart failure, achieving a promising 2-year event-free survival rate with new-generation devices. Currently, this technology has spread throughout the world, and any cardiologist or cardiac surgeon should be familiar with its fundamentals and its possible complications as well as the advances made in recent years. The aim of this review is to describe current knowledge, management of complications, and future directions of this novel heart-failure therapy

Abstract

Long-term continuous-flow left ventricular assist devices have become a real alternative to heart transplantation in patients with advanced heart failure, achieving a promising 2-year event-free survival rate with new-generation devices. Currently, this technology has spread throughout the world, and any cardiologist or cardiac surgeon should be familiar with its fundamentals and its possible complications as well as the advances made in recent years. The aim of this review is to describe current knowledge, management of complications, and future directions of this novel heart-failure therapy

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

continuous flow, mechanical circulatory support, left ventricular assist device

About this article
Title

Continuous-flow left ventricular assist device: Current knowledge, complications, and future directions

Journal

Cardiology Journal

Issue

Vol 29, No 2 (2022)

Article type

Review Article

Pages

293-304

Published online

2021-12-28

Page views

6479

Article views/downloads

2285

DOI

10.5603/CJ.a2021.0172

Pubmed

34967940

Bibliographic record

Cardiol J 2022;29(2):293-304.

Keywords

continuous flow
mechanical circulatory support
left ventricular assist device

Authors

Javier Castrodeza
Carlos Ortiz-Bautista
Francisco Fernández-Avilés

References (100)
  1. McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 36: 3599–3726.
    CrossRefPubMed
  2. Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021; 77(6): 772–810.
    CrossRefPubMed
  3. Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. Eur J Heart Fail. 2017; 19(5): 595–602.
    CrossRefPubMed
  4. Rose E, Gelijns A, Moskowitz A, et al. Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure. N Engl J Med. 2001; 345(20): 1435–1443.
    CrossRef
  5. Mehra MR, Uriel N, Naka Y, et al. A fully magnetically levitated left ventricular assist device - final report. N Engl J Med. 2019; 380(17): 1618–1627.
    CrossRefPubMed
  6. Metra M, Eichhorn E, Abraham WT, et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009; 30(24): 3015–3026.
    CrossRefPubMed
  7. Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation. 2007; 115(2): 204–212.
    CrossRefPubMed
  8. Goldstein DJ, Meyns B, Xie R, et al. Third annual report from the ISHLT mechanically assisted circulatory support registry: a comparison of centrifugal and axial continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2019; 38(4): 352–363.
    CrossRefPubMed
  9. Netuka I, Sood P, Pya Y, et al. Fully magnetically levitated left ventricular assist system for treating advanced HF: a multicenter study. J Am Coll Cardiol. 2015; 66(23): 2579–2589.
    CrossRefPubMed
  10. Zimpfer D, Netuka I, Schmitto JD, et al. Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomes. Eur J Cardiothorac Surg. 2016; 50(3): 548–554.
    CrossRefPubMed
  11. Krabatsch T, Netuka I, Schmitto JD, et al. Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure -1 year results from the Ce mark trial. J Cardiothorac Surg. 2017; 12(1): 23.
    CrossRefPubMed
  12. Schmitto JD, Pya Y, Zimpfer D, et al. Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study. Eur J Heart Fail. 2019; 21(1): 90–97.
    CrossRefPubMed
  13. Bourque K, Cotter C, Dague C, et al. Design rationale and preclinical evaluation of the heartmate 3 left ventricular assist system for hemocompatibility. ASAIO J. 2016; 62(4): 375–383.
    CrossRefPubMed
  14. Lim HS, Howell N, Ranasinghe A. The physiology of continuous-flow left ventricular assist devices. J Card Fail. 2017; 23(2): 169–180.
    CrossRefPubMed
  15. Miller LW, Rogers JG. Evolution of left ventricular assist device therapy for advanced heart failure: a review. JAMA Cardiol. 2018; 3(7): 650–658.
    CrossRefPubMed
  16. Potapov EV, Netuka I, Kaufmann F, et al. Strategy for surgical correction and mitigation of outflow graft twist with a centrifugal-flow left ventricular assist system. J Heart Lung Transplant. 2018; 37(5): 670–673.
    CrossRefPubMed
  17. Abbott Recalls the HeartMate 3TM Left Ventricular Assist System Due to Potential Malfunction that may Lead to Graft Occlusion. https://www.fda.gov/medical-devices/medical-device-recalls/abbott-recalls-heartmate-3tm-leftventricular-assist-system-due-potential malfunction-may-lead-graft..
  18. Rivas-Lasarte M, Scatola A, Sims DB, et al. A new twist to HeartMate 3 low flow alarms. Rev Esp Cardiol (Engl Ed). 2021; 74(4): 349–351.
    CrossRefPubMed
  19. Hanke JS, Rojas SV, Dogan G, et al. First series of left ventricular assist device exchanges to HeartMate 3. Eur J Cardiothorac Surg. 2017; 51(5): 887–892.
    CrossRefPubMed
  20. Saito S, Nishinaka T. Chronic nonpulsatile blood flow is compatible with normal end-organ function: implications for LVAD development. J Artif Organs. 2005; 8(3): 143–148.
    CrossRefPubMed
  21. Uriel N, Adatya S, Malý J, et al. Clinical hemodynamic evaluation of patients implanted with a fully magnetically levitated left ventricular assist device (HeartMate 3). J Heart Lung Transplant. 2017; 36(1): 28–35.
    CrossRefPubMed
  22. Dobarro D, Urban M, Booth K, et al. Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device. J Heart Lung Transplant. 2017; 36(1): 42–49.
    CrossRefPubMed
  23. John R, Mantz K, Eckman P, et al. Aortic valve pathophysiology during left ventricular assist device support. J Heart Lung Transplant. 2010; 29(12): 1321–1329.
    CrossRefPubMed
  24. Bartoli CR, Giridharan GA, Litwak KN, et al. Hemodynamic responses to continuous versus pulsatile mechanical unloading of the failing left ventricle. ASAIO J. 2010; 56(5): 410–416.
    CrossRefPubMed
  25. Healy C, Viles-Gonzalez JF, Sacher F, et al. Management of ventricular arrhythmias in patients with mechanical ventricular support devices. Curr Cardiol Rep. 2015; 17(8): 59.
    CrossRefPubMed
  26. Long B, Robertson J, Koyfman A, et al. Left ventricular assist devices and their complications: A review for emergency clinicians. Am J Emerg Med. 2019; 37(8): 1562–1570.
    CrossRefPubMed
  27. Kiamanesh O, Kaan A, Toma M. Medical management of left ventricular assist device patients: a practical guide for the nonexpert clinician. Can J Cardiol. 2020; 36(2): 205–215.
    CrossRefPubMed
  28. O'Horo JC, Abu Saleh OM, Stulak JM, et al. Left ventricular assist device infections: a systematic review. ASAIO J. 2018; 64(3): 287–294.
    CrossRefPubMed
  29. Schlöglhofer T, Michalovics P, Riebandt J, et al. Left ventricular assist device driveline infections in three contemporary devices. Artif Organs. 2021; 45(5): 464–472.
    CrossRefPubMed
  30. Blanco-Guzman MO, Wang X, Vader JM, et al. Epidemiology of left ventricular assist device infections: findings from a large nonregistry cohort. Clin Infect Dis. 2021; 72(2): 190–197.
    CrossRefPubMed
  31. John R, Aaronson KD, Pae WE, et al. HeartWare Bridge to Transplant ADVANCE Trial Investigators. Drive-line infections and sepsis in patients receiving the HVAD system as a left ventricular assist device. J Heart Lung Transplant. 2014; 33(10): 1066–1073.
    CrossRefPubMed
  32. Shah P, Mehta VM, Cowger JA, et al. Diagnosis of hemolysis and device thrombosis with lactate dehydrogenase during left ventricular assist device support. J Heart Lung Transplant. 2014; 33(1): 102–104.
    CrossRefPubMed
  33. Uriel N, Han J, Morrison KA, et al. Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon. J Heart Lung Transplant. 2014; 33(1): 51–59.
    CrossRefPubMed
  34. Schrottmaier WC, Kral JB, Zeitlinger M, et al. Platelet activation at the onset of human endotoxemia is undetectable in vivo. Platelets. 2016; 27(5): 479–483.
    CrossRefPubMed
  35. Park SJ, Milano CA, Tatooles AJ, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012; 5(2): 241–248.
    CrossRefPubMed
  36. Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013; 32(2): 157–187.
    CrossRefPubMed
  37. Cagliostro B, Levin AP, Fried J, et al. Continuous-flow left ventricular assist devices and usefulness of a standardized strategy to reduce drive-line infections. J Heart Lung Transplant. 2016; 35(1): 108–114.
    CrossRefPubMed
  38. Kimura Y, Seguchi O, Mochizuki H, et al. Role of Gallium-SPECT-CT in the Management of Patients With Ventricular Assist Device-Specific Percutaneous Driveline Infection. J Card Fail. 2019; 25(10): 795–802.
    CrossRefPubMed
  39. Koval CE, Stosor V. AST ID Community of Practice. Ventricular assist device-related infections and solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33(9): e13552.
    CrossRefPubMed
  40. Aslam S. Ventricular assist device infections. Cardiol Clin. 2018; 36(4): 507–517.
    CrossRefPubMed
  41. Truby LK, Garan AR, Givens RC, et al. Aortic insufficiency during contemporary left ventricular assist device support: analysis of the INTERMACS registry. JACC Heart Fail. 2018; 6(11): 951–960.
    CrossRefPubMed
  42. Jorde UP, Uriel N, Nahumi N, et al. Prevalence, significance, and management of aortic insufficiency in continuous flow left ventricular assist device recipients. Circ Heart Fail. 2014; 7(2): 310–319.
    CrossRefPubMed
  43. Pak SW, Uriel N, Takayama H, et al. Prevalence of de novo aortic insufficiency during long-term support with left ventricular assist devices. J Heart Lung Transplant. 2010; 29(10): 1172–1176.
    CrossRefPubMed
  44. Kirklin JK, Pagani FD, Goldstein DJ, et al. Editors, Contributing Authors, Reviewers. American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support. J Heart Lung Transplant. 2020; 39(3): 187–219.
    CrossRefPubMed
  45. Imamura T, Narang N, Kim G, et al. Impact of worsening of aortic insufficiency during HeartMate 3 LVAD support. Artif Organs. 2021; 45(3): 297–302.
    CrossRefPubMed
  46. Kiamanesh O, Kaan A, Toma M. Medical management of left ventricular assist device patients: a practical guide for the nonexpert clinician. Can J Cardiol. 2020; 36(2): 205–215.
    CrossRefPubMed
  47. Bhagra SK, Pettit S, Parameshwar J. Implantable left ventricular assist device: indications, eligibility and current outcomes. Heart. 2021 [Epub ahead of print].
    CrossRefPubMed
  48. Yehya A, Rajagopal V, Meduri C, et al. Short-term results with transcatheter aortic valve replacement for treatment of left ventricular assist device patients with symptomatic aortic insufficiency. J Heart Lung Transplant. 2019; 38(9): 920–926.
    CrossRefPubMed
  49. Fried JA, Nazif TM, Colombo PC. A new frontier for TAVR: Aortic insufficiency in CF-LVAD patients. J Heart Lung Transplant. 2019; 38(9): 927–929.
    CrossRefPubMed
  50. van der Werf HW, Schurer RAj, Vonck TE, et al. Emergency transcatheter aortic valve implantation in patients with severe aortic regurgitation and a left ventricle assist device: A case report and systematic review. Eur Heart J Acute Cardiovasc Care. 2017; 6(8): 719–727.
    CrossRefPubMed
  51. Parikh KS, Mehrotra AK, Russo MJ, et al. Percutaneous transcatheter aortic valve closure successfully treats left ventricular assist device-associated aortic insufficiency and improves cardiac hemodynamics. JACC Cardiovasc Interv. 2013; 6(1): 84–89.
    CrossRefPubMed
  52. Cowger J, Rao V, Massey T, et al. Comprehensive review and suggested strategies for the detection and management of aortic insufficiency in patients with a continuous-flow left ventricular assist device. J Heart Lung Transplant. 2015; 34(2): 149–157.
    CrossRefPubMed
  53. Bellavia D, Iacovoni A, Scardulla C, et al. Prediction of right ventricular failure after ventricular assist device implant: systematic review and meta-analysis of observational studies. Eur J Heart Fail. 2017; 19(7): 926–946.
    CrossRefPubMed
  54. Cogswell R, John R, Shaffer A. Right ventricular failure after left ventricular assist device. Cardiol Clin. 2020; 38(2): 219–225.
    CrossRefPubMed
  55. Benjamin MM, Sundararajan S, Sulaiman S, et al. Association of preoperative duration of inotropy on prevalence of right ventricular failure following LVAD implantation. ESC Heart Fail. 2020; 7(4): 1949–1955.
    CrossRefPubMed
  56. Lampert BC, Teuteberg JJ. Right ventricular failure after left ventricular assist devices. J Heart Lung Transplant. 2015; 34(9): 1123–1130.
    CrossRefPubMed
  57. Turner KR. Right ventricular failure after left ventricular assist device placement-the beginning of the end or just another challenge? J Cardiothorac Vasc Anesth. 2019; 33(4): 1105–1121.
    CrossRefPubMed
  58. Ruiz-Cano MJ, Morshuis M, Koster A, et al. Risk factors of early right ventricular failure in patients undergoing LVAD implantation with intermediate Intermacs profile for advanced heart failure. J Card Surg. 2020; 35(8): 1832–1839.
    CrossRefPubMed
  59. Ali HJR, Kiernan MS, Choudhary G, et al. Right ventricular failure post-implantation of left ventricular assist device: prevalence, pathophysiology, and predictors. ASAIO J. 2020; 66(6): 610–619.
    CrossRefPubMed
  60. Lampert BC, Teuteberg JJ. Right ventricular failure after left ventricular assist devices. J Heart Lung Transplant. 2015; 34(9): 1123–1130.
    CrossRefPubMed
  61. Raina A, Patarroyo-Aponte M. Prevention and treatment of right ventricular failure during left ventricular assist device therapy. Crit Care Clin. 2018; 34(3): 439–452.
    CrossRefPubMed
  62. Mondal S, Sankova S, Lee K, et al. Intraoperative and early postoperative management of patients undergoing minimally invasive left ventricular assist device implantation. J Cardiothorac Vasc Anesth. 2021; 35(2): 616–630.
    CrossRefPubMed
  63. Fitzpatrick JR, Frederick JR, Hiesinger W, et al. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg. 2009; 137(4): 971–977.
    CrossRefPubMed
  64. Gopinathannair R, Cornwell WK, Dukes JW, et al. Device therapy and arrhythmia management in left ventricular assist device recipients: a scientific statement from the american heart association. Circulation. 2019; 139(20): e967–e989.
    CrossRefPubMed
  65. Caraang C, Lanier GM, Gass A, et al. Left ventricular assist device in older adults. Heart Fail Clin. 2017; 13(3): 619–632.
    CrossRefPubMed
  66. Bohonos CJ, Bechtum EL, Luckhardt AJ, et al. Ventricular tachycardia and preload deficiency post LVAD: the importance of integrated assessment. Heart Lung. 2020; 49(5): 481–487.
    CrossRefPubMed
  67. Cantillon DJ, Tarakji KG, Kumbhani DJ, et al. Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. Heart Rhythm. 2010; 7(4): 466–471.
    CrossRefPubMed
  68. Refaat MM, Tanaka T, Kormos RL, et al. Survival benefit of implantable cardioverter-defibrillators in left ventricular assist device-supported heart failure patients. J Card Fail. 2012; 18(2): 140–145.
    CrossRefPubMed
  69. Enriquez AD, Calenda B, Miller MA, et al. The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices. Circ Arrhythm Electrophysiol. 2013; 6(4): 668–674.
    CrossRefPubMed
  70. Garan AR, Yuzefpolskaya M, Colombo PC, et al. Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention? J Am Coll Cardiol. 2013; 61(25): 2542–2550.
    CrossRefPubMed
  71. Lee W, Tay A, Subbiah RN, et al. Impact of implantable cardioverter defibrillators on survival of patients with centrifugal left ventricular assist devices. Pacing Clin Electrophysiol. 2015; 38(8): 925–933.
    CrossRefPubMed
  72. Vakil K, Kazmirczak F, Sathnur N, et al. Implantable cardioverter-defibrillator use in patients with left ventricular assist devices: a systematic review and meta-analysis. JACC Heart Fail. 2016; 4(10): 772–779.
    CrossRefPubMed
  73. Bartoli CR, Ghotra AS, Pachika AR, et al. Hematologic markers better predict left ventricular assist device thrombosis than echocardiographic or pump parameters. Thorac Cardiovasc Surg. 2014; 62(5): 414–418.
    CrossRefPubMed
  74. Adatya S, Holley CT, Roy SS, et al. Echocardiographic Ramp test for continuous-flow left ventricular assist devices: do loading conditions matter? JACC Heart Fail. 2015; 3(4): 291–299.
    CrossRefPubMed
  75. Kato TS, Colombo PC, Nahumi N, et al. Value of serial echo-guided ramp studies in a patient with suspicion of device thrombosis after left ventricular assist device implantation. Echocardiography. 2014; 31(1): E5–E9.
    CrossRefPubMed
  76. Barac YD, Nevo A, Schroder JN, et al. LVAD outflow graft role in pump thrombosis. ASAIO J. 2020; 66(2): 128–131.
    CrossRefPubMed
  77. Stulak JM, Sharma S, Maltais S. Management of pump thrombosis in patients with left ventricular assist devices. Am J Cardiovasc Drugs. 2015; 15(2): 89–94.
    CrossRefPubMed
  78. Hanke JS, Dogan G, Wert L, et al. Left ventricular assist device exchange for the treatment of HeartMate II pump thrombosis. J Thorac Dis. 2018; 10(Suppl 15): S1728–S1736.
    CrossRefPubMed
  79. Giede-Jeppe A, Roeder SS, Macha K, et al. Management of stroke in patients with left ventricular assist devices. J Stroke Cerebrovasc Dis. 2020; 29(11): 105166.
    CrossRefPubMed
  80. Kuśmierczyk M, Różański J, Zembala M, et al. Heart failure in Poland: left ventricular assist device destination therapy and other challenges of interventional cardiology and cardiac surgery. Cardiol J. 2020; 27(6): 693–704.
    CrossRefPubMed
  81. Netuka I, Ivák P, Tučanová Z, et al. Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump-the MAGENTUM 1 study. J Heart Lung Transplant. 2018; 37(5): 579–586.
    CrossRefPubMed
  82. Kadakkal A, Najjar SS. Neurologic events in continuous-flow left ventricular assist devices. Cardiol Clin. 2018; 36(4): 531–539.
    CrossRefPubMed
  83. Kataria R, Jorde UP. Gastrointestinal bleeding during continuous-flow left ventricular assist device support: state of the field. Cardiol Rev. 2019; 27(1): 8–13.
    CrossRefPubMed
  84. Klovaite J, Gustafsson F, Mortensen SA, et al. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol. 2009; 53(23): 2162–2167.
    CrossRefPubMed
  85. Sakatsume Ko, Saito K, Akiyama M, et al. Association between the severity of acquired von Willebrand syndrome and gastrointestinal bleeding after continuous-flow left ventricular assist device implantation. Eur J Cardiothorac Surg. 2018; 54(5): 841–846.
    CrossRefPubMed
  86. Crow S, Chen D, Milano C, et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg. 2010; 90(4): 1263–9; discussion 1269.
    CrossRefPubMed
  87. Schmitto JD, Molitoris U, Haverich A, et al. Implantation of a centrifugal pump as a left ventricular assist device through a novel, minimized approach: upper hemisternotomy combined with anterolateral thoracotomy. J Thorac Cardiovasc Surg. 2012; 143(2): 511–513.
    CrossRefPubMed
  88. Maltais S, Davis ME, Haglund N. Minimally invasive and alternative approaches for long-term LVAD placement: the Vanderbilt strategy. Ann Cardiothorac Surg. 2014; 3(6): 563–569.
    CrossRefPubMed
  89. Reichart D, Brand CF, Bernhardt AM, et al. Analysis of minimally invasive left thoracotomy HVAD implantation: a single-center experience. Thorac Cardiovasc Surg. 2019; 67(3): 170–175.
    CrossRefPubMed
  90. McGee E, Danter M, Strueber M, et al. Evaluation of a lateral thoracotomy implant approach for a centrifugal-flow left ventricular assist device: The LATERAL clinical trial. J Heart Lung Transplant. 2019; 38(4): 344–351.
    CrossRefPubMed
  91. Wieselthaler GM, Klein L, Cheung AW, et al. Two-year follow up of the LATERAL clinical trial: a focus on adverse events. Circ Heart Fail. 2021; 14(4): e006912.
    CrossRefPubMed
  92. Mohite PN, Sabashnikov A, Raj B, et al. Minimally invasive left ventricular assist device implantation: a comparative study. Artif Organs. 2018; 42(12): 1125–1131.
    CrossRefPubMed
  93. Maltais S, Anwer LA, Tchantchaleishvili V, et al. Left lateral thoracotomy for centrifugal continuous-flow left ventricular assist device placement: an analysis from the mechanical circulatory support research network. ASAIO J. 2018; 64(6): 715–720.
    CrossRefPubMed
  94. Pasrija C, Sawan MA, Sorensen E, et al. Less invasive left ventricular assist device implantation may reduce right ventricular failure. Interact Cardiovasc Thorac Surg. 2019; 29(4): 592–598.
    CrossRefPubMed
  95. Kormos RL, Cowger J, Pagani FD, et al. The society of thoracic surgeons intermacs database annual report: evolving indications, outcomes, and scientific partnerships. J Heart Lung Transplant. 2019; 38(2): 114–126.
    CrossRefPubMed
  96. Kocabeyoglu SS, Kervan U, Sert DE, et al. Is it Possible to Implant HeartMate 3 Less Invasively? New Pump, New Approach. Artif Organs. 2018; 42(12): 1132–1138.
    CrossRefPubMed
  97. Dowling RD, Gray LA, Etoch SW, et al. Initial experience with the AbioCor implantable replacement heart system. J Thorac Cardiovasc Surg. 2004; 127(1): 131–141.
    CrossRefPubMed
  98. Pae WE, Connell JM, Adelowo A, et al. Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart experience in Europe. J Heart Lung Transplant. 2007; 26(3): 219–229.
    CrossRefPubMed
  99. Pya Y, Maly J, Bekbossynova M, et al. First human use of a wireless coplanar energy transfer coupled with a continuous-flow left ventricular assist device. J Heart Lung Transplant. 2019; 38(4): 339–343.
    CrossRefPubMed
  100. Mehra MR, Gustafsson F. Left ventricular assist devices at the crossroad of innovation in advanced heart failure. J Card Fail. 2021; 27(11): 1291–1294.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl